Abstract
Bunyaviridae family consists of vector borne lethal viruses, stands out as the largest virus family with its 350 members. One such virus of this family, Crimean- Congo hemorrhagic fever virus (CCHFV) is transmitted through bites of ixodid ticks or by direct contact with blood from infected animals. Crimean-Congo haemorrhagic fever (CCHF) is a severe disease in humans which is endemic in large parts of the world with a high mortality rate. This virus could also be used as a bioterrorism agent due to its human-to-human transmission with no specific therapy. The pathogenicity factor of CCHFV is unexplored due to the lack of animal models. CCHFV, being an RNA virus, is able to mutate rapidly hence preventing the development of effective therapy against it. Till now ribavarin is the only available drug for supportive treatment but has many side-effects. New technologies like RNA interference have emerged as a solution for epidemics of CCHF. RNAi is a sequence specific approach, has been used successfully against different pathogens. This review focuses on designing and application of RNAi with emphasis on the role of bioinformatics for the anti CCHFV therapeutic development strategy.
Keywords: Crimean-Congo hemorrhagic fever, CCHFV, bunyaviridae, nairoviridae, RNAi, siRNA, epidemiology, glycoproteins, antiviral therapy, nucleoprotein
Current Bioinformatics
Title:Crimean-Congo Hemorrhagic Fever Virus: Strategies to Combat with an Emerging Threat to Human
Volume: 7 Issue: 4
Author(s): Shivendra Pratap, Manju Narwal, Aditya Dev, Sonali Dhindwal, Shailly Tomar and Pravindra Kumar
Affiliation:
Keywords: Crimean-Congo hemorrhagic fever, CCHFV, bunyaviridae, nairoviridae, RNAi, siRNA, epidemiology, glycoproteins, antiviral therapy, nucleoprotein
Abstract: Bunyaviridae family consists of vector borne lethal viruses, stands out as the largest virus family with its 350 members. One such virus of this family, Crimean- Congo hemorrhagic fever virus (CCHFV) is transmitted through bites of ixodid ticks or by direct contact with blood from infected animals. Crimean-Congo haemorrhagic fever (CCHF) is a severe disease in humans which is endemic in large parts of the world with a high mortality rate. This virus could also be used as a bioterrorism agent due to its human-to-human transmission with no specific therapy. The pathogenicity factor of CCHFV is unexplored due to the lack of animal models. CCHFV, being an RNA virus, is able to mutate rapidly hence preventing the development of effective therapy against it. Till now ribavarin is the only available drug for supportive treatment but has many side-effects. New technologies like RNA interference have emerged as a solution for epidemics of CCHF. RNAi is a sequence specific approach, has been used successfully against different pathogens. This review focuses on designing and application of RNAi with emphasis on the role of bioinformatics for the anti CCHFV therapeutic development strategy.
Export Options
About this article
Cite this article as:
Pratap Shivendra, Narwal Manju, Dev Aditya, Dhindwal Sonali, Tomar Shailly and Kumar Pravindra, Crimean-Congo Hemorrhagic Fever Virus: Strategies to Combat with an Emerging Threat to Human, Current Bioinformatics 2012; 7 (4) . https://dx.doi.org/10.2174/157489312803900901
DOI https://dx.doi.org/10.2174/157489312803900901 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Influence of Natural Substrates and Inhibitors on the Nucleotide- Dependent Excision Activity of HIV-1 Reverse Transcriptase in the Infected Cell
Current Pharmaceutical Design Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Bridging Over the Troubled Heterogeneity of SPG-Related Pathologies: Mechanisms Unite What Genetics Divide
Current Molecular Medicine Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Towards More Successful Gene Therapy Clinical Trials for β-Thalassemia
Current Molecular Medicine Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets Zn Finger Containing Proteins as Targets for the Control of Viral Infections
Infectious Disorders - Drug Targets Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology
Current Medicinal Chemistry Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform
Current Pharmaceutical Design Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews Relationship Among Fatty Liver, Adipose Tissue Distribution and Metabolic Profile in Moderately Obese Children: An Ultrasonographic Study
Current Pharmaceutical Design Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology